@article{SCI11699,
author = {Terek Wehbe and Majid Abi Saab and Nassim Abi Chahine and Talar Margossian},
title = {Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases},
journal = {Stem Cell Investigation},
volume = {3},
number = {9},
year = {2016},
keywords = {},
abstract = {We treated 2 patients with progressive, refractory scleroderma with a combined immunotherapy approach using plasmapheresis followed by rituximab and then intravenous umbilical-cord-derived allogeneic mesenchymal stem cells (MSCs). Both patients improved subjectively and objectively for over a year. Upon recurrence of their symptoms, the patients were treated again with allogeneic MSCs alone with a very good response. The combination was well tolerated and effective suggesting a large scale study may be warranted in progressive, refractory Scleroderma.},
issn = {2313-0792}, url = {https://sci.amegroups.org/article/view/11699}
}